Phase II study of anlotinib for treatment of advanced medullary thyroid carcinoma.

Sun, Yongkun; Chi, Yihebali; Tang, Ping-zhang; Gao, Ming; Ji, Qinghai; Li, Zhendong; Zhang, Yuan; Z, Guo; Wang, Jun; Chen, Xiangjing

doi:10.1200/jco.2016.34.15_suppl.6015

Cited by 8 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The average PFS was 12.8 months (median PFS not reached), the overall ORR was 48.28% (full analysis set, FAS), and the DCR at weeks 24 and 48 was 92.16% and 84.53%, respectively. These results indicate that anlotinib has the potential to treat advanced MTC [ 57 ].…”

Section: Therapeutic Efficacy Of Anlotinibmentioning

confidence: 99%

“… OS (median, months, control group). Author Ref Advanced NSCLC II (randomized control) 117 10.0 0.00 4.8 1.2 9.30 6.30 Han B [ 25 ] Advanced NSCLC III 437 9.18 0.7 5.37 1.40 9.63 6.30 Han B [ 26 ] Advanced STS II (single-arm) 166 11.45 / 5.63 / NA / Chi Y [ 42 ] Advanced STS IIB (randomized control) 233 10.13 1.33 6.27 1.47 NA NA Chi Y [ 44 ] mRCC II (single-arm) 43 19.1 / 11.8 (whole group);8.5(progressed on a TKI group) / NA NA Zhou A P [ 50 ] mRCC II (randomized control) 133 24.4 23.3 11.3 11.0 NA NA Zhou AP [ 51 ] Advanced MTC II (single-arm) 58 48.28 / 12.8 / NA / Sun Y [ 57 ] NSCLC non-small-cell lung cancer, ORR overall response rate, PFS progression-free surv...…”

Section: Therapeutic Efficacy Of Anlotinibmentioning

confidence: 99%

“…Anlotinib had a similar toxicity in another phase I trial and a manageable AE profile in phase II–III trials. Among 58 patients with advanced MTC who received anlotinib treatment in a phase II study, 20.7% required a dose adjustment to 10 mg daily in a 2 weeks on/1 week off schedule because of grade III/IV AEs [ 57 ]. It is noteworthy that 5 of 166 patients (3.01%) with advanced STS treated with anlotinib experienced grade III/IV pneumothorax [ 42 ].…”

Section: Anlotinib Tolerabilitymentioning

confidence: 99%

See 2 more Smart Citations

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development

et al. 2018

View full text Add to dashboard Cite

Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. Compared to the effect of placebo, it improved both progression-free survival (PFS) and overall survival (OS) in a phase III trial in patients with advanced non-small-cell lung cancer (NSCLC), despite progression of the cancer after two lines of prior treatments. Recently, the China Food and Drug Administration (CFDA) approved single agent anlotinib as a third-line treatment for patients with advanced NSCLC. Moreover, a randomized phase IIB trial demonstrated that anlotinib significantly prolonged the median PFS in patients with advanced soft tissue sarcoma (STS). Anlotinib also showed promising efficacy in patients with advanced medullary thyroid carcinoma and metastatic renal cell carcinoma (mRCC). The tolerability profile of anlotinib is similar to that of other tyrosine kinase inhibitors that target VEGFR and other tyrosine kinase-mediated pathways; however, anlotinib has a significantly lower incidence of grade 3 or higher side effects compared to that of sunitinib. We review the rationale, clinical evidence, and future perspectives of anlotinib for the treatment of multiple cancers.

show abstract

Section: Therapeutic Efficacy Of Anlotinibmentioning

confidence: 99%

Section: Therapeutic Efficacy Of Anlotinibmentioning

confidence: 99%

Section: Anlotinib Tolerabilitymentioning

confidence: 99%

See 1 more Smart Citation

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Even if in these models (which are easy to produce) the progression of MTC can be easily monitored, evidence indicates that the xenograft models might not be adequate for the prediction of a clinical response. Effectively, in spite of several studies performed in preclinical models and in clinical trials, only few compounds (vandetanib and cabozantinib) have been approved for the treatment of advanced or metastatic MTC in humans, while few others (sunitinib and anlotinib) have been evaluated in phase II study [16,17]. The possibility to develop in the future transgenic models to test the efficacy of antineoplastic drugs could represent an attractive alternative method.…”

Section: Expert Opinionmentioning

confidence: 99%

Mouse models of medullary thyroid cancer and developing new targeted therapies

Paragliola

Torino

Papi

et al. 2016

Expert Opinion on Drug Discovery

View full text Add to dashboard Cite

“…Clinical trials have proven the effective anticancer activity of anlotinib in advanced non-small-cell lung cancer (NSCLC) [22,23], advanced soft tissue sarcoma (STS) [24,25], advanced medullary thyroid cancer (MTC) [26,27], and metastatic renal cell carcinoma (mRCC) [28]. However, the anticancer activity of anlotinib as a third-line treatment for mCRC requires more evidence.…”

mentioning

confidence: 99%

Third-line treatment for metastatic colorectal cancer: anlotinib is superior to chemotherapy and similar to fruquintinib or regorafenib

Cheng¹,

Du²,

Fang³

et al. 2021

neo

View full text Add to dashboard Cite

The clinical efficiency and adverse reactions of anlotinib in metastatic colorectal cancer (mCRC) as a third-line treatment compared with chemotherapy and regorafenib or fruquintinib was explored in this study. Clinical data from 105 mCRC patients who failed at least two lines of chemotherapy were collected. The patients were divided into three groups based on their third-line therapeutic regimen: third-line chemotherapy only (group A); anlotinib (group B); and fruquintinib or regorafenib (group C). The result showed that the ORR and DCR of group B (14.29 %, 85.71%) were higher than those of group A (0%, 40.00%). The ORRs of group B and group C were 14.29% and 20.00%, respectively. Group B and group C had the same DCR, 85.71%. The mean PFS values of group B (3.46 months) and group C (3.33 months) were longe and the mean PFS values of group B and group C we of group B was 9 0.001). The mean OS values of group B (9.22 months) and group C (9.38 months) we re not hand-foot skin reaction, myelosuppression, and gastrointestinal reaction were similar be tween group B and group C (P = 0.173, 0.188, 1.00, 0.154, respectively). Myelosuppression and gastrointestinal reaction were more common in group A than in group B and group C (P < 0.001). For mCRC, anlotinib as a third-line treatment is better than chemotherapy and similar to regorafenib or fruquintinib. The associated adverse reactions are tolerable.

show abstract

Phase II study of anlotinib for treatment of advanced medullary thyroid carcinoma.

Cited by 8 publications

References 0 publications

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development

Mouse models of medullary thyroid cancer and developing new targeted therapies

Third-line treatment for metastatic colorectal cancer: anlotinib is superior to chemotherapy and similar to fruquintinib or regorafenib

Contact Info

Product

Resources

About